Emerging Diabetes Technology Driven By Patient Demands
Integration has become a key driver in the development of a new wave of diabetes tools that have either recently hit the market or will become available in the next few years. Many diabetics, who have a great deal of influence on the success or failure of products in this space, are seeking devices that work seamlessly with the smart phones and cellular technology that are so prevalent today. A number of start-up companies are poised to compete with the bigger diabetes manufacturers as the market continues to evolve.
You may also be interested in...
Remote monitoring is proving to be the driving force in the industry’s quest to reduce costs by keeping patients out of hospitals, and telemedicine is positioned to become a major part of that scheme. However, telemedicine has a number of components and players, and while the market offers opportunities, it could also prove to be somewhat disruptive to companies and products that do not fit in the envisioned landscape.
The market for insulin delivery devices is positioned to change significantly with several manufacturers gearing their products toward type 2 diabetics, who make up 90% to 95% of the diabetes patient pool in the US. These new, “pump-like” devices could offer the type 2 diabetes population better control in managing glucose levels, a solution the medical community has been seeking for a while.
Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.